XSHE
002275
Market cap1.07bUSD
Oct 09, Last price
12.35CNY
1D
1.31%
1Q
-5.87%
Jan 2017
-32.77%
IPO
-51.45%
Name
Guilin Sanjin Pharmaceutical Co.
Chart & performance
P/E
16.75
P/S
3.55
EPS
0.74
Div yield, %
4.51%
Shrs. gr., 5y
0.35%
Rev. gr., 5y
5.48%
Revenues
2.05b
-6.76%
Net income
433m
-16.95%
CFO
708m
+20.36%
Dividend
Jun 04, 20260.3 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Guilin Sanjin Pharmaceutical Co., Ltd. is a Chinese pharmaceutical firm dedicated to the research, production, and distribution of traditional Chinese and natural medicines across China. Established in 1967 and headquartered in Guilin, the company's product portfolio prominently features well-known traditional Chinese medicine (TCM) brands such as Guilin watermelon frost and lozenge, Sanjin tablets, and Naomaitai capsules. Beyond these core offerings, it also manufactures a range of other TCM preparations. The company operates as a subsidiary of the broader Guilin SanJin Group Co.,Ltd.
Key people
Xufei Wang
Vice Chairman of the Board, President · since 2013
Yuangang Xie
Finance Director, Vice President, Director · since 2016
Zhun Zou
Vice President · since 2013
Chang Qing Zhu
Director · since 2010
Jieming Zou
Chairman of the Board
Xun Zou
Vice President, Secretary of the Board, Director · since 2010
Independent Director · since 2013
Jun Sun
Independent Director · since 2013
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||